Bone-Rad

Executive Summary

Bone-Rad Therapeutics is a privately held medical device company headquartered in Dublin, Ireland, focused on developing Spine-Rad™ Cement, an innovative treatment for tumors in bone and soft tissue. Founded in 2016, the company aims to address the limitations of current therapies—such as invasive surgery and radiation—with a minimally invasive, cost-effective cement that delivers localized radiation. The technology integrates diagnostic and therapeutic capabilities, potentially offering a paradigm shift in managing metastatic and primary bone tumors. Bone-Rad's approach could improve patient outcomes by reducing treatment times, hospital stays, and side effects. Although Bone-Rad remains in early commercialization stages with no disclosed financials or clinical data, its niche in the growing interventional oncology market positions it for significant impact. The company's success hinges on securing regulatory clearances, demonstrating clinical efficacy, and establishing partnerships for distribution. With an experienced management team and a clear unmet need, Bone-Rad represents a speculative opportunity in the oncology-device space. Near-term catalysts include regulatory submissions and trial initiations that could validate its technology and attract strategic investors.

Upcoming Catalysts (preview)

• Q1 2027FDA IDE Submission for Spine-Rad Cement Study60% success
• Q4 2026CE Marking Application to European Notified Body65% success
• Q2 2027First Patient Enrolled in Pivotal Clinical Trial50% success